Search Results - "MC Minnema"

Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy by Minnema, M C, Breitkreutz, I, Auwerda, J J A, van der Holt, B, Cremer, F W, van Marion, A M W, Westveer, P H M, Sonneveld, P, Goldschmidt, H, Lokhorst, H M

Get full text

Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment by Minnema, M. C., Fijnheer, R., De Groot, P. G., Lokhorst, H. M.

“…Venous thromboembolism (VTE) is a major complication in patients with multiple myeloma (MM) during treatment with thalidomide combined with chemotherapy and/or…”
Get full text

TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D (GPRC5D) CD3 BISPECIFIC ANTIBODY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 STUDY RESULTS by JG Berdeja, AY Krishnan, A Oriol, NWV Donk, P Rodríguez-Otero, E Askari, M Mateos, MC Minnema, LJ Costa, R Verona, BW Hilderq, S Girgisq, T Prior, JS Russell, JD Goldberg, A Chari

“…Objectives: Patients with MM continue to relapse on current therapies, stressing the need for new immunotherapy targets. GPRC5D is an orphan receptor that is…”
Get full text

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study by Tam, Constantine S., Opat, Stephen, D'Sa, Shirley, Jurczak, Wojciech, Lee, Hui-Peng, Cull, Gavin, Owen, Roger G., Marlton, Paula, Wahlin, Björn E., Sanz, Ramón Garcia, McCarthy, Helen, Mulligan, Stephen, Tedeschi, Alessandra, Castillo, Jorge J., Czyz, Jaroslaw, Fernández de Larrea, Carlos, Belada, David, Libby, Edward, Matous, Jeffrey V., Motta, Marina, Siddiqi, Tanya, Tani, Monica, Trneny, Marek, Minnema, Monique C., Buske, Christian, Leblond, Veronique, Trotman, Judith, Chan, Wai Y., Schneider, Jingjing, Ro, Sunhee, Cohen, Aileen, Huang, Jane, Dimopoulos, Meletios

“…Bruton tyrosine kinase (BTK) inhibition is an effective treatment approach for patients with Waldenström macroglobulinemia (WM). The phase 3 ASPEN study…”
Get full text

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma by Lokhorst, Henk M, Plesner, Torben, Laubach, Jacob P, Nahi, Hareth, Gimsing, Peter, Hansson, Markus, Minnema, Monique C, Lassen, Ulrik, Krejcik, Jakub, Palumbo, Antonio, van de Donk, Niels W.C.J, Ahmadi, Tahamtan, Khan, Imran, Uhlar, Clarissa M, Wang, Jianping, Sasser, A. Kate, Losic, Nedjad, Lisby, Steen, Basse, Linda, Brun, Nikolai, Richardson, Paul G

“…Daratumumab was associated with impressive antitumor responses, including complete and very good partial responses, in heavily pretreated patients with…”
Get full text

Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia by Leblond, Véronique, Kastritis, Efstathios, Advani, Ranjana, Ansell, Stephen M., Buske, Christian, Castillo, Jorge J., García-Sanz, Ramón, Gertz, Morie, Kimby, Eva, Kyriakou, Charalampia, Merlini, Giampaolo, Minnema, Monique C., Morel, Pierre, Morra, Enrica, Rummel, Mathias, Wechalekar, Ashutosh, Patterson, Christopher J., Treon, Steven P., Dimopoulos, Meletios A.

“…Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined criteria for the diagnosis, initiation of…”
Get full text

Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients by Oostvogels, Rimke, Jak, Margot, Raymakers, Reinier, Mous, Rogier, Minnema, Monique C.

“…Summary This single‐centre retrospective observational study analysed the efficacy of retreatment with immunomodulatory agents (IMiDs) and proteasome…”
Get full text

Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study by Dimopoulos, Meletios A, Opat, Stephen, D'Sa, Shirley, Jurczak, Wojciech, Lee, Hui-Peng, Cull, Gavin, Owen, Roger G, Marlton, Paula, Wahlin, Björn E, Garcia-Sanz, Ramon, McCarthy, Helen, Mulligan, Stephen, Tedeschi, Alessandra, Castillo, Jorge J, Czyz, Jaroslaw, Fernández de Larrea, Carlos, Belada, David, Libby, Edward, Matous, Jeffrey, Motta, Marina, Siddiqi, Tanya, Tani, Monica, Trněný, Marek, Minnema, Monique C, Buske, Christian, Leblond, Veronique, Treon, Steven P, Trotman, Judith, Chan, Wai Y, Schneider, Jingjing, Allewelt, Heather, Patel, Sheel, Cohen, Aileen, Tam, Constantine S

“…The phase III ASPEN study demonstrated the comparable efficacy and improved safety of zanubrutinib versus ibrutinib in patients with Waldenström…”
Get full text

Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome by Minnema, Monique C, Kimby, Eva, D'Sa, Shirley, Fornecker, Luc-Matthieu, Poulain, Stéphanie, Snijders, Tom J, Kastritis, Efstathios, Kremer, Stéphane, Fitsiori, Aikaterini, Simon, Laurence, Davi, Frédéric, Lunn, Michael, Castillo, Jorge J, Patterson, Christopher J, Le Garff-Tavernier, Magali, Costopoulos, Myrto, Leblond, Véronique, Kersten, Marie-José, Dimopoulos, Meletios A, Treon, Steven P

“…Bing Neel syndrome is a rare disease manifestation of Waldenström's macroglobulinemia that results from infiltration of the central nervous system by malignant…”
Get full text

Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria by Treon, Steven P., Tedeschi, Alessandra, San-Miguel, Jesus, Garcia-Sanz, Ramon, Anderson, Kenneth C., Kimby, Eva, Minnema, Monique C., Benevolo, Giulia, Qiu, Lugui, Yi, Shuhui, Terpos, Evangelos, Tam, Constantine S., Castillo, Jorge J., Morel, Pierre, Dimopoulos, Meletios, Owen, Roger G.

“…Consensus Panel 4 (CP4) of the 11th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11) was tasked with reviewing the current criteria for…”
Get full text

Long-Lasting Remissions for Myeloma Patients on Daratumumab Therapy from the GEN501 and GEN503 Trials by Szabo, Agoston Gyula, Minnema, Monique C, Nahi, Hareth, Plesner, Torben

“…Introduction The first two trials to test the activity of daratumumab (DARA) in relapsed/refractory multiple myeloma (MM) were GEN501 (DARA monotherapy) and…”
Get full text

Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study by Lonial, Sagar, Grosicki, Sebastian, Hus, Marek, Song, Kevin W., Facon, Thierry, Callander, Natalie Scott, Ribrag, Vincent, Uttervall, Katarina, Quach, Hang, Vorobyev, Vladimir I., Min, Chang Ki, Cheng, Shinta, Smith, L. Mary, Yu, Jing, Collingwood, Therese, Holkova, Beata, Kremer, Brandon, Gupta, Ira, Richardson, Paul G., Minnema, Monique C.

“…8019 Background: Preclinical data demonstrate that nirogacestat, a gamma-secretase inhibitor, may increase cell-surface levels of a B-cell maturation antigen…”
Get full text

DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma by Callander, Natalie S., Ribrag, Vincent, Richardson, Paul G., Nooka, Ajay K., Song, Kevin, Uttervall, Katarina, Minnema, Monique C., Weisel, Katja, Quach, Hang, Min, Chang-Ki, Ballas, Marc S., Li, Xiaofang, Ratia, Nirav, Kaisermann, Morrys, Holkova, Beata, Trudel, Suzanne

“…Introduction: Single-agent belantamab mafodotin (belamaf), a B-cell maturation antigen-targeting antibody-drug conjugate, achieved durable responses with a…”
Get full text

Liposomal drug delivery in an in vitro 3D bone marrow model for multiple myeloma by Braham, Maaike Vj, Deshantri, Anil K, Minnema, Monique C, Öner, F Cumhur, Schiffelers, Raymond M, Fens, Marcel Ham, Alblas, Jacqueline

“…Liposomal drug delivery can improve the therapeutic index of treatments for multiple myeloma. However, an appropriate 3D model for the in vitro evaluation of…”
Get full text

Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016 by Rutten, Karlijn H. G., Raymakers, Reinier A. P., Hazenberg, Bouke P. C., Nienhuis, Hans L. A., Vellenga, Edo, Minnema, Monique C.

“…Background: Although survival has improved in recent decades, the short-term prognosis of patients with immunoglobulin light chain (AL) amyloidosis remains…”
Get full text

Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia by Tam, Constantine S., Opat, Stephen, D'Sa, Shirley, Jurczak, Wojciech, Lee, Hui-Peng, Cull, Gavin, Owen, Roger G., Marlton, Paula, Wahlin, Björn E., García-Sanz, Ramón, McCarthy, Helen, Mulligan, Stephen, Tedeschi, Alessandra, Castillo, Jorge J., Czyż, Jarosław, Fernández De Larrea, Carlos, Belada, David, Libby, Edward, Matous, Jeffrey, Motta, Marina, Siddiqi, Tanya, Tani, Monica, Trněný, Marek, Minnema, Monique C., Buske, Christian, Leblond, Véronique, Treon, Steven P., Trotman, Judith, Wu, Binghao, Yu, Yiling, Shen, Zhirong, Chan, Wai Y., Schneider, Jingjing, Allewelt, Heather, Cohen, Aileen, Dimopoulos, Meletios A.

“…•Patients with Waldenström macroglobulinemia and mutations in CXCR4 or TP53 had poorer prognosis after treatment with BTKis.•Patients with CXCR4 or TP53…”
Get full text

Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival by Lokhorst, Henk M, van der Holt, Bronno, Cornelissen, Jan J, Kersten, Marie José, van Oers, Marinus, Raymakers, Reinier, Minnema, Monique C, Zweegman, Sonja, Bos, Gerard, Schaap, Nicolaas, Wittebol, Shulamiet, de Weerdt, Okke, Ammerlaan, Rianne, Sonneveld, Pieter

Get full text

Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial by van de Donk, Niels WCJ, van der Holt, Bronno, Minnema, Monique C, Vellenga, Edo, Croockewit, Sandra, Kersten, Marie José, von dem Borne, Peter A, Ypma, Paula, Schaafsma, Ron, de Weerdt, Okke, Klein, Saskia K, Delforge, Michel, Levin, Mark-David, Bos, Gerard M, Jie, Kon-Siong G, Sinnige, Harm, Coenen, Jules LLM, de Waal, Esther G, Zweegman, Sonja, Sonneveld, Pieter, Lokhorst, Henk M

“…In patients with recently diagnosed multiple myeloma, the HOVON-50 phase 3 trial showed improved event-free survival for thalidomide-containing induction and…”
Get full text

DREAMM-5 platform trial: Belantamab mafodotin (belamaf; GSK2857916) in combination with five different novel agents in patients with relapsed/refractory multiple myeloma (RRMM) by Richardson, PG, Trudel, S, Callander, NS, Nooka, A, Song, K, Uttervall, K, Minnema, MC, Rodriguez-Otero, P, Struemper, H, Yeakey, A, de Oca, RM, Smith, LM, Jackson, N, Kaisermann, M, Im, E, Basile, FG, Ahlers, CM, Holkova, B, Gupta, I, Kremer, BE, Quach, H

Get full text

Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli by Minnema, M.C., Chang, A. C.K., Jansen, P.M., Lubbers, Y. T.P., Pratt, B.M., Whittaker, B.G., Taylor, F.B., Hack, C.E., Friedman, B.

“…Plasma-derived antithrombin III (ATIII) prevents the lethal effects of Escherichia coli infusion in baboons, but the mechanisms behind this effect are not…”
Get full text